Anastrozole (Arimidex) for Endometriosis
Anastrozole is not a standard first-line treatment for endometriosis and is not FDA-approved for this indication, but it can be considered as an adjunctive therapy in refractory cases, particularly when combined with other hormonal treatments after conservative surgery. 1
Current Guideline-Based Standard Treatment
The established medical therapies for endometriosis include progestins, danazol, oral contraceptives, NSAIDs, and GnRH agonists—none of which include aromatase inhibitors like anastrozole 2. These standard treatments have Level A evidence supporting their efficacy for pain relief, with GnRH agonists for at least 3 months or danazol for at least 6 months being equally effective 2.
FDA Approval Status
Arimidex is FDA-approved exclusively for breast cancer treatment in postmenopausal women, not for endometriosis 1. The drug label makes no mention of endometriosis as an indication, and its use for this condition would be off-label.
Evidence for Off-Label Use in Endometriosis
Despite lacking guideline support or FDA approval, research evidence suggests potential benefit in specific scenarios:
Post-Surgical Adjunctive Therapy
- The strongest evidence comes from a 2004 randomized trial showing that 6 months of anastrozole plus goserelin after conservative surgery significantly reduced symptom recurrence compared to goserelin alone (7.5% vs 35% recurrence at 24 months; relative risk 4.3) 3
- A 2021 trial demonstrated that anastrozole combined with levonorgestrel-IUD (Mirena) for 6 months starting one month before surgery reduced painful symptoms by 51% and delayed recurrence, though this was only effective when paired with conservative surgery—not with ultrasound-guided aspiration alone 4
Refractory Cases
- A 2005 phase 2 trial showed 14 of 15 patients with refractory endometriosis achieved significant pain reduction (55% median decrease) using anastrozole 1 mg daily combined with low-dose oral contraceptives for 6 months 5
- Case reports document successful treatment of severe, treatment-resistant endometriosis in both premenopausal and postmenopausal women 6, 7
Clinical Algorithm for Consideration
Use anastrozole only in these specific circumstances:
- After failure of standard therapies (oral contraceptives, progestins, GnRH agonists) 2
- As adjunctive therapy following conservative surgery for severe endometriosis 4, 3
- Always combined with:
- Duration: 6 months 4, 3, 5
- Dose: 1 mg daily 4, 5
Critical Safety Considerations
Bone Mineral Density Loss
Anastrozole causes reduction in bone mineral density 1. When combined with GnRH agonists, bone loss is more pronounced but recovers within 2 years of treatment withdrawal 3. Monitor bone density and provide calcium/vitamin D supplementation 1.
Pregnancy Risk
Anastrozole may cause fetal harm and is contraindicated in pregnancy 1. Effective contraception is mandatory in premenopausal women, which is why combination with oral contraceptives or levonorgestrel-IUD is essential 4, 5.
Other Adverse Effects
- Elevated cholesterol (9% of patients) 1
- Joint disorders, arthralgia 1
- Hot flashes, though less than with tamoxifen 1
Common Pitfalls to Avoid
- Do not use anastrozole as monotherapy—it must be combined with progestins or GnRH agonists to prevent follicular development and provide contraception 4, 5
- Do not use without prior surgical intervention in severe cases—the evidence shows benefit primarily as post-surgical adjunctive therapy 4, 3
- Do not use as first-line therapy—reserve for refractory cases after standard treatments have failed 2, 5
- Do not combine with estrogen-containing therapies—they diminish anastrozole's pharmacological action 1
Bottom Line
While anastrozole shows promise in research settings for refractory endometriosis, it remains an off-label, non-guideline-supported option that should be reserved for severe, treatment-resistant cases as adjunctive post-surgical therapy, always combined with appropriate hormonal suppression and contraception. Standard guideline-recommended therapies should be exhausted first 2.